Screening and treatment of latent tuberculosis among healthcare workers at low, moderate, and high risk for tuberculosis exposure: A cost-effectiveness analysis

Infection Control and Hospital Epidemiology

Volumn 25, Issue 12, 2004, Pages 1056-1061

  Salpeter, Shelley R ^a,b   Salpeter, Edwin E ^c  

^a SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Department of Obstetrics Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID;

ARTICLE; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DEATH; DRUG COST; HEALTH CARE COST; HEALTH CARE PERSONNEL; HIGH RISK POPULATION; INFECTION RISK; LIFE EXPECTANCY; OCCUPATIONAL EXPOSURE; SCREENING TEST; STATISTICAL MODEL; TREATMENT OUTCOME; TUBERCULIN TEST; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; COST-BENEFIT ANALYSIS; DECISION TREES; HEALTH PERSONNEL; HUMANS; ISONIAZID; MARKOV CHAINS; MASS SCREENING; RISK FACTORS; TUBERCULIN TEST; TUBERCULOSIS;

EID: 10844259851     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/502343     Document Type: Article

References (48)

1. Barrett-Connor E. The epidemiology of tuberculosis in physicians. JAMA 1979;241:33-38.
2. Sepkowitz KA. Tuberculosis and the health care worker, a historical perspective. Ann Intern Med 1994;120:71-79.
3. Field MJ, Institute of Medicine, Committee on Regulating Occupational Exposure to Tuberculosis. Tuberculosis in the Workplace. Washington, DC: National Academy Press; 2001:xiv, 340.
4. Sepkowitz KA, Friedman CR, Hafner A, et al. Tuberculosis among urban health care workers: a study using restriction fragment length polymorphism typing. Clin Infect Dis 1995;21:1098-1101.
5. McKenna MT, Hutton M, Cauthen G, Onorato IM. The association between occupation and tuberculosis: a population-based survey. Am J Respir Crit Care Med 1996;154:587-593.
6. Centers for Disease Control and Prevention. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care facilities, 1994. MMWR 1994;43:1-132.
7. Bratcher DF, Stover BH, Lane NE, Paul RI. Compliance with national recommendations for tuberculosis screening and immunization of healthcare workers in a children's hospital. Infect Control Hosp Epidemiol 2000;21:338-340.
8. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making 1983;3:419-458.
9. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322-338.
10. National Center for Health Statistics. Monthly Vital Statistics Report: Annual Summary of Births, Marriages, Divorces and Deaths: United States, 2001. Washington, DC: U.S. Public Health Service; 2001.
11. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis: a general review. Bibliotheca Tuberculosei 1970;26:28-106.
12. Comstock GW, Ferebee SH, Hammes LM. A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis 1967;95:935-943.
13. Comstock GW, Woolpert SF, Livesay VT. Tuberculosis studies in Muscogee County, Georgia: twenty-year evaluation of a community trial of BCG vaccination. Public Health Rep 1976;91:276-280.
14. Schneider E, Castro KG. Tuberculosis trends in the United States, 1992-2001. Tuberculosis (Edinb) 2003;83:21-29.
15. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement: global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. JAMA 1999;282:677-686.
16. Salpeter EE, Salpeter SR. Mathematical model for the epidemiology of tuberculosis, with estimates of the reproductive number and infection-delay function. Am J Epidemiol 1998;147:398-406.
17. Salpeter SR, Sanders GD, Salpeter EE, Owens DK. Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis. Ann Intern Med 1997;127:1051-1061.
18. Grzybowski S, Ashley MJ, McKinnon NE, Pinkus G, Philipps R, Brown A. In Canada: a trial of chemoprophylaxis in inactive tuberculosis. Canadian Medical Association Journal 1969;101:81-86.
19. Grzybowski S, Ashley MJ, Pinkus G. Chemoprophylaxis in inactive tuberculosis: long-term evaluation of a Canadian trial. Canadian Medical Association Journal 1976;114:607-611.
20. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ 1982;60:555-564.
21. Stead WW, To T, Harrison RW, Abraham JH 3rd. Benefit-risk considerations in preventive treatment for tuberculosis in elderly persons. Ann Intern Med 1987;107:843-845.
22. Espinal MA, Laszlo A, Simonsen L, et al. Global trends in resistance to antituberculosis drugs. N Engl J Med 2001;344:1294-1303.
23. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR 2000;49:1-51.
24. Snider DE Jr, Caras GJ, Koplan JP. Preventive therapy with isoniazid: cost-effectiveness of different durations of therapy. JAMA 1986;255:1579-1583.
25. Salpeter SR. Fatal isoniazid-induced hepatitis: its risk during chemoprophylaxis. West J Med 1993;159:560-564.
26. Millard PS, Wilcosky TC, Reade-Christopher SJ, Weber DJ. Isoniazid-related fatal hepatitis. West J Med 1996;164:486-491.
27. Mohle-Boetani JC, Miller B, Halpern M, et al. School-based screening for tuberculous infection: a cost-benefit analysis. JAMA 1995;274:613-619.
28. Fitzgerald JM, Gafni A. A cost-effectiveness analysis of the routine use of isoniazid prophylaxis in patients with a positive Mantoux skin test Am Rev Respir Dis 1990;142:848-853.
29. Brown RE, Miller B, Taylor WR, et al. Health-care expenditures for tuberculosis in the United States. Arch Intern Med 1995;155:1595-1600.
30. Bureau of Labor Statistics. Consumer Price Index. Washington, DC: Bureau of Labor Statistics; 2002.
31. Miller AK, Tepper A, Sieber K. Historical risks of tuberculin skin test conversion among non-physician staff at a large urban hospital. Am J Ind Med 2002;42:228-235.
32. Panlilio AL, Burwen DR, Curtis AB, et al. Tuberculin skin testing surveillance of health care personnel. Clin Infect Dis 2002;35:219-227.
33. Warren DK, Foley KM, Polish LB, Seiler SM, Fraser VJ. Tuberculin skin testing of physicians at a midwestern teaching hospital: a 6-year prospective study. Clin Infect Dis 2001;32:1331-1337.
34. Swinker M. Prevalence of positive tuberculin skin reactions in a two-step testing program at a tertiary-care center in eastern North Carolina. Infect Control Hosp Epidemiol 2000;21:39-40.
35. Behrman AJ, Shofer FS. Tuberculosis exposure and control in an urban emergency department. Ann Emerg Med 1998;31:370-375.
36. Blumberg HM, Sotir M, Erwin M, Bachman R, Shulman JA. Risk of house staff tuberculin skin test conversion in an area with a high incidence of tuberculosis. Clin Infect Dis 1998;27:826-833.
37. Christie CD, Constantinou P, Marx ML, et al. Low risk for tuberculosis in a regional pediatric hospital: nine-year study of community rates and the mandatory employee tuberculin skin-test program. Infect Control Hosp Epidemiol 1998;19:168-174.
38. LoBue PA, Catanzaro A. Effectiveness of a nosocomial tuberculosis control program at an urban teaching hospital. Chest 1998;113:1184-1189.
39. Louther J, Rivera P, Feldman J, Villa N, DeHovitz J, Sepkowitz KA. Risk of tuberculin conversion according to occupation among health care workers at a New York City hospital. Am J Respir Crit Care Med 1997;156:201-205.
40. Zahnow K, Matts JP, Hillman D, et al. Rates of tuberculosis infection in healthcare workers providing services to HIV-infected populations: Terry Beirn Community Programs for Clinical Research on AIDS. Infect Control Hosp Epidemiol 1998;19:829-835.
41. Ball R, Van Wey M. Tuberculosis skin test conversion among health care workers at a military medical center. Mil Med 1997;162:338-343.
42. Bangsberg DR, Crowley K, Moss A, Dobkin JF, McGregor C, Neu HC. Reduction in tuberculin skin-test conversions among medical house staff associated with improved tuberculosis infection control practices. Infect Control Hosp Epidemiol 1997;18:566-570.
43. Boudreau AY, Baron SL, Steenland NK, et al. Occupational risk of Mycobacterium tuberculosis infection in hospital workers. Am J Ind Med 1997;32:528-534.
44. Manusov EG, Bradshaw RD, Fogarty JP. Tuberculosis screening in medical students. Fam Med 1996;28:645-649.
45. Sinkowitz RL, Fridkin SK, Manangan L, Wenger PN, Jarvis WR. Status of tuberculosis infection control programs at United States hospitals, 1989 to 1992. Am J Infect Control 1996;24:226-234.
46. Bailey TC, Fraser VJ, Spitznagel EL, Dunagan WC. Risk factors for a positive tuberculin skin test among employees of an urban, midwestern teaching hospital. Ann Intern Med 1995;122:580-585.
47. Fraser VJ, Kilo CM, Bailey TC, Medoff G, Dunagan WC. Screening of physicians for tuberculosis. Infect Control Hosp Epidemiol 1994;15:95-100.
48. Trends in tuberculosis morbidity: United States, 1992-2002. MMWR 2003;52:217-220, 222.